AKRO
Akero Therapeutics, Inc.
19.91
USD
This page is just a preview of the data found in TrendSpider’s full version
Akero Therapeutics, Inc. stock is up 41.41% since 30 days ago. The next earnings date is Mar 15, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 4 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 8 PUTs, 2 CALLs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 16 Nov 18:53 | 16 Feb, 2024 | 35.00 | 370 | ||
| 16 Nov 19:05 | 16 Feb, 2024 | 35.00 | 370 | ||
| 27 Nov 16:11 | 19 Jan, 2024 | 25.00 | 353 | ||
| 27 Nov 16:11 | 19 Jan, 2024 | 25.00 | 353 | ||
| 27 Nov 16:13 | 16 Feb, 2024 | 30.00 | 59 | ||
| 28 Nov 17:34 | 19 Jan, 2024 | 25.00 | 331 | ||
| 28 Nov 17:36 | 16 Feb, 2024 | 30.00 | 51 | ||
| 29 Nov 17:59 | 17 May, 2024 | 22.50 | 11 | ||
| 01 Dec 18:51 | 19 Jan, 2024 | 22.50 | 38 | ||
| 07 Dec 18:44 | 17 May, 2024 | 25.00 | 97 |
Akero Therapeutics, Inc. engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins.
